Aquinox Pharmaceuticals Company Profile (NASDAQ:AQXP)

About Aquinox Pharmaceuticals (NASDAQ:AQXP)

Aquinox Pharmaceuticals logoAquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company's primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway. Its product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. AQX-1125 is a SHIP1 activator that has demonstrated preliminary safety, anti-inflammatory potential and drug properties in multiple preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AQXP
  • CUSIP: N/A
  • Web: www.aqxpharma.com
Capitalization:
  • Market Cap: $320.9 million
  • Outstanding Shares: 23,423,000
Average Prices:
  • 50 Day Moving Avg: $14.48
  • 200 Day Moving Avg: $16.01
  • 52 Week Range: $6.01 - $19.97
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.40
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $5.85 per share
  • Price / Book: 2.34
Profitability:
  • Return on Equity: -27.43%
  • Return on Assets: -25.84%
Debt:
  • Current Ratio: 17.13%
  • Quick Ratio: 17.13%
Misc:
  • Average Volume: 97,829 shs.
  • Beta: -17.36
  • Short Ratio: 20.38
 

Frequently Asked Questions for Aquinox Pharmaceuticals (NASDAQ:AQXP)

What is Aquinox Pharmaceuticals' stock symbol?

Aquinox Pharmaceuticals trades on the NASDAQ under the ticker symbol "AQXP."

How were Aquinox Pharmaceuticals' earnings last quarter?

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) issued its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.15. During the same quarter last year, the firm posted ($0.39) earnings per share. View Aquinox Pharmaceuticals' Earnings History.

Where is Aquinox Pharmaceuticals' stock going? Where will Aquinox Pharmaceuticals' stock price be in 2017?

5 equities research analysts have issued 1-year price targets for Aquinox Pharmaceuticals' stock. Their predictions range from $9.00 to $28.00. On average, they expect Aquinox Pharmaceuticals' share price to reach $20.75 in the next year. View Analyst Ratings for Aquinox Pharmaceuticals.

Are investors shorting Aquinox Pharmaceuticals?

Aquinox Pharmaceuticals saw a decline in short interest in April. As of April 28th, there was short interest totalling 1,550,505 shares, a decline of 19.6% from the April 13th total of 1,928,076 shares. Based on an average trading volume of 76,041 shares, the short-interest ratio is currently 20.4 days. Approximately 7.0% of the company's shares are sold short.

Who are some of Aquinox Pharmaceuticals' key competitors?

Who owns Aquinox Pharmaceuticals stock?

Aquinox Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include RA Capital Management LLC (9.32%), Goldman Sachs Group Inc. (4.13%), Boxer Capital LLC (3.75%), Vanguard Group Inc. (0.00%), Eventide Asset Management LLC (0.75%) and Royce & Associates LP (0.00%). Company insiders that own Aquinox Pharmaceuticals stock include Bros Advisors Lp Baker, David Chilton Mitchell, Kamran Alam and Lloyd Mackenzie. View Institutional Ownership Trends for Aquinox Pharmaceuticals.

Who sold Aquinox Pharmaceuticals stock? Who is selling Aquinox Pharmaceuticals stock?

Aquinox Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Emory University, Royce & Associates LP, RA Capital Management LLC, ProShare Advisors LLC, Goldman Sachs Group Inc., TD Asset Management Inc. and Bank of New York Mellon Corp. View Insider Buying and Selling for Aquinox Pharmaceuticals.

Who bought Aquinox Pharmaceuticals stock? Who is buying Aquinox Pharmaceuticals stock?

Aquinox Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Geode Capital Management LLC and Investment Centers of America Inc.. Company insiders that have bought Aquinox Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker and David Chilton Mitchell. View Insider Buying and Selling for Aquinox Pharmaceuticals.

How do I buy Aquinox Pharmaceuticals stock?

Shares of Aquinox Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Aquinox Pharmaceuticals stock cost?

One share of Aquinox Pharmaceuticals stock can currently be purchased for approximately $13.70.

Analyst Ratings

Consensus Ratings for Aquinox Pharmaceuticals (NASDAQ:AQXP) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $20.75 (51.46% upside)

Analysts' Ratings History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/9/2017Cantor FitzgeraldSet Price TargetBuy$28.00LowView Rating Details
11/11/2016Leerink SwannReiterated RatingBuy$24.00N/AView Rating Details
11/10/2016Needham & Company LLCReiterated RatingBuyN/AView Rating Details
8/17/2016Canaccord GenuityReiterated RatingBuy$22.00N/AView Rating Details
8/5/2016Jefferies Group LLCBoost Price TargetHold$7.00 -> $9.00N/AView Rating Details
11/3/2015Cowen and CompanyReiterated RatingBuy$23.00N/AView Rating Details
10/6/2015GuggenheimInitiated CoverageBuy$22.00N/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Earnings by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Earnings History by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/20173/31/2017($0.51)($0.36)ViewN/AView Earnings Details
3/9/201712/31/2016($0.51)($0.48)ViewListenView Earnings Details
11/9/2016Q316($0.58)($0.46)ViewN/AView Earnings Details
8/4/2016Q2($0.41)($0.63)ViewN/AView Earnings Details
5/10/2016Q1($0.35)($0.39)ViewN/AView Earnings Details
11/10/2015Q315($0.45)($0.43)ViewN/AView Earnings Details
8/6/2015Q215($0.56)($0.44)ViewN/AView Earnings Details
5/12/2015Q115($0.83)($0.60)ViewN/AView Earnings Details
4/15/2015($0.57)($0.78)ViewN/AView Earnings Details
3/16/2015Q4 2014($0.76)($0.78)ViewN/AView Earnings Details
11/4/2014Q3 2014($0.29)($0.59)ViewN/AView Earnings Details
8/11/2014Q2 2014($0.27)($0.51)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aquinox Pharmaceuticals (NASDAQ:AQXP)
2017 EPS Consensus Estimate: ($2.43)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.57)($0.57)($0.57)
Q2 20171($0.59)($0.59)($0.59)
Q3 20171($0.62)($0.62)($0.62)
Q4 20171($0.65)($0.65)($0.65)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Insider Ownership Percentage: 3.00%
Institutional Ownership Percentage: 97.78%
Insider Trades by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Institutional Ownership by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Insider Trades by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/9/2017Bros. Advisors Lp BakerMajor ShareholderBuy398,062$17.18$6,838,705.16View SEC Filing  
9/20/2016Bros. Advisors Lp BakerMajor ShareholderBuy2,783,605$12.25$34,099,161.25View SEC Filing  
3/16/2016Bros. Advisors Lp BakerMajor ShareholderBuy471,667$7.99$3,768,619.33View SEC Filing  
3/15/2016Bros. Advisors Lp BakerMajor ShareholderBuy109,912$7.98$877,097.76View SEC Filing  
1/26/2016Bros. Advisors Lp BakerMajor ShareholderBuy140,786$10.80$1,520,488.80View SEC Filing  
1/20/2016Bros. Advisors Lp BakerMajor ShareholderBuy112,034$9.48$1,062,082.32View SEC Filing  
1/19/2016Bros. Advisors Lp BakerMajor ShareholderBuy78,045$9.11$710,989.95View SEC Filing  
1/15/2016Bros. Advisors Lp BakerMajor ShareholderBuy202,623$8.28$1,677,718.44View SEC Filing  
9/10/2015Bros. Advisors Lp BakerMajor ShareholderBuy2,480,032$15.50$38,440,496.00View SEC Filing  
8/24/2015David Chilton MitchellVPBuy3,575$17.81$63,670.75View SEC Filing  
8/12/2015Kamran AlamCFOSell29,079$18.67$542,904.93View SEC Filing  
8/12/2015Lloyd MackenzieVPSell35,887$18.67$670,010.29View SEC Filing  
12/17/2014& Johnson JohnsonMajor ShareholderSell8,100$7.62$61,722.00View SEC Filing  
12/12/2014& Johnson JohnsonMajor ShareholderSell5,000$7.51$37,550.00View SEC Filing  
12/10/2014& Johnson JohnsonMajor ShareholderSell8,300$7.72$64,076.00View SEC Filing  
12/9/2014& Johnson JohnsonMajor ShareholderSell5,000$7.73$38,650.00View SEC Filing  
12/8/2014& Johnson JohnsonMajor ShareholderSell2,000$7.69$15,380.00View SEC Filing  
12/5/2014& Johnson JohnsonMajor ShareholderSell15,900$7.76$123,384.00View SEC Filing  
12/1/2014& Johnson JohnsonMajor ShareholderSell1,200$7.54$9,048.00View SEC Filing  
11/26/2014& Johnson JohnsonMajor ShareholderSell2,000$7.75$15,500.00View SEC Filing  
11/24/2014& Johnson JohnsonMajor ShareholderSell9,500$8.14$77,330.00View SEC Filing  
3/12/2014Pfizer IncMajor ShareholderBuy272,727$11.00$2,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Latest Headlines for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Source:
DateHeadline
americanbankingnews.com logoAquinox Pharmaceuticals Inc Forecasted to Earn FY2017 Earnings of ($2.24) Per Share (AQXP)
www.americanbankingnews.com - May 15 at 8:54 AM
americanbankingnews.com logoShort Interest in Aquinox Pharmaceuticals Inc (AQXP) Declines By 19.6%
www.americanbankingnews.com - May 14 at 9:14 AM
americanbankingnews.com logoAquinox Pharmaceuticals Inc (AQXP) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 12 at 2:38 PM
americanbankingnews.com logoAquinox Pharmaceuticals Inc (AQXP) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - May 11 at 10:52 PM
reuters.com logoBRIEF-Aquinox Pharmaceuticals Qtrly loss per share $0.36
www.reuters.com - May 11 at 3:59 PM
americanbankingnews.com logoResearch Analysts Issue Forecasts for Aquinox Pharmaceuticals Inc's FY2017 Earnings (AQXP)
www.americanbankingnews.com - May 11 at 11:42 AM
americanbankingnews.com logoAquinox Pharmaceuticals Inc (AQXP) Given a $28.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - May 9 at 11:36 PM
americanbankingnews.com logoZacks Investment Research Downgrades Aquinox Pharmaceuticals Inc (AQXP) to Hold
www.americanbankingnews.com - May 9 at 4:38 PM
finance.yahoo.com logoAquinox Pharmaceuticals Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 3:35 PM
finance.yahoo.com logoAquinox reports 1Q loss
finance.yahoo.com - May 9 at 3:35 PM
americanbankingnews.com logoAquinox Pharmaceuticals Inc (AQXP) Announces Earnings Results, Beats Estimates By $0.15 EPS
www.americanbankingnews.com - May 9 at 11:24 AM
americanbankingnews.com logoAquinox Pharmaceuticals Inc (AQXP) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - May 5 at 11:12 PM
americanbankingnews.com logoAquinox Pharmaceuticals Inc (AQXP) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - May 5 at 10:46 PM
americanbankingnews.com logoAquinox Pharmaceuticals Inc (AQXP) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - May 5 at 10:23 PM
americanbankingnews.com logoAquinox Pharmaceuticals (AQXP) Earns News Sentiment Rating of 0.10
www.americanbankingnews.com - May 2 at 7:26 PM
americanbankingnews.com logoZacks: Brokerages Expect Aquinox Pharmaceuticals Inc (AQXP) to Announce -$0.57 Earnings Per Share
www.americanbankingnews.com - May 1 at 7:46 PM
americanbankingnews.com logoAquinox Pharmaceuticals (AQXP) Given Daily Coverage Optimism Rating of 0.04
www.americanbankingnews.com - April 27 at 2:42 PM
finance.yahoo.com logoAquinox to Present at 2017 Bloom Burton & Co. Healthcare Investor Conference
finance.yahoo.com - April 26 at 8:58 AM
americanbankingnews.com logoAquinox Pharmaceuticals (AQXP) Receives Daily News Sentiment Score of 0.02
www.americanbankingnews.com - April 23 at 8:22 AM
americanbankingnews.com logoSomewhat Favorable Media Coverage Very Unlikely to Affect Aquinox Pharmaceuticals (AQXP) Share Price
www.americanbankingnews.com - April 20 at 2:40 PM
americanbankingnews.com logoAquinox Pharmaceuticals Inc (AQXP) Sees Large Decline in Short Interest
www.americanbankingnews.com - April 19 at 7:08 AM
americanbankingnews.com logoAquinox Pharmaceuticals Inc (AQXP) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 17 at 5:08 PM
americanbankingnews.com logoAquinox Pharmaceuticals (AQXP) Receiving Somewhat Critical News Coverage, Report Finds
www.americanbankingnews.com - April 17 at 12:04 PM
americanbankingnews.com logoSomewhat Favorable Press Coverage Somewhat Likely to Impact Aquinox Pharmaceuticals (AQXP) Stock Price
www.americanbankingnews.com - April 14 at 4:40 PM
americanbankingnews.com logoAquinox Pharmaceuticals Inc (AQXP) Expected to Post Quarterly Sales of $0.00
www.americanbankingnews.com - April 12 at 11:56 AM
finance.yahoo.com logoAquinox to Present at the 16th Annual Needham Healthcare Conference
finance.yahoo.com - March 29 at 8:48 PM
streetinsider.com logoAquinox Pharma (AQXP) Names Kelvin Neu and Richard Levy to Board of Directors
www.streetinsider.com - March 28 at 10:31 AM
biz.yahoo.com logoAQUINOX PHARMACEUTICALS, INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and
biz.yahoo.com - March 28 at 10:31 AM
finance.yahoo.com logoAquinox Announces Appointment of Dr. Kelvin Neu and Dr. Richard Levy to Board of Directors
finance.yahoo.com - March 28 at 10:31 AM
finance.yahoo.com logo6:23 pm Aquinox Pharma announced that representatives from Aquinox's largest shareholder, Baker Brothers Investments, have been appointed to the Aquinox's board of directors
finance.yahoo.com - March 28 at 10:31 AM
americanbankingnews.com logoAquinox Pharmaceuticals Inc (AQXP) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - March 23 at 6:25 PM
americanbankingnews.com logoAquinox Pharmaceuticals Inc (AQXP) to Post FY2017 Earnings of ($2.30) Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - March 23 at 9:32 AM
seekingalpha.com logoAquinox Pharmaceuticals (AQXP) Presents At Oppenheimer 27th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 22 at 9:08 PM
americanbankingnews.com logoAquinox Pharmaceuticals Inc (AQXP) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 22 at 12:46 PM
americanbankingnews.com logoAquinox Pharmaceuticals Inc (AQXP) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 20 at 9:55 AM
biz.yahoo.com logoAQUINOX PHARMACEUTICALS, INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 16 at 5:06 PM
finance.yahoo.com logoAQUINOX PHARMACEUTICALS, INC Financials
finance.yahoo.com - March 15 at 3:47 PM
finance.yahoo.com logoAquinox to Present at the Oppenheimer & Co. 27th Annual Healthcare Conference
finance.yahoo.com - March 14 at 8:35 PM
americanbankingnews.com logoAquinox Pharmaceuticals Inc Forecasted to Post FY2021 Earnings of $0.30 Per Share (AQXP)
www.americanbankingnews.com - March 13 at 2:48 PM
americanbankingnews.com logoAquinox Pharmaceuticals Inc (AQXP) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - March 11 at 7:21 PM
seekingalpha.com logoAquinox Pharmaceuticals' (AQXP) CEO David Main on Q4 2016 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 10 at 4:21 PM
biz.yahoo.com logoAQUINOX PHARMACEUTICALS, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
biz.yahoo.com - March 9 at 9:13 PM
biz.yahoo.com logoQ4 2016 Aquinox Pharmaceuticals Inc Earnings Release - After Market Close
biz.yahoo.com - March 9 at 4:12 PM
finance.yahoo.com logoAquinox Pharmaceuticals Announces Year End 2016 Financial Results
finance.yahoo.com - March 9 at 4:12 PM
fool.com logoCan Shares of Aquinox Pharmaceuticals Continue to Rocket Higher? - Motley Fool
www.fool.com - March 1 at 5:30 AM
fool.com logoCan Shares of Aquinox Pharmaceuticals Continue to Rocket Higher?
www.fool.com - February 28 at 10:28 AM
finance.yahoo.com logoAquinox to Present at Leerink Partners 6th Annual Global Healthcare Conference
finance.yahoo.com - February 9 at 3:41 PM
thestreet.com logo5 Stocks Insiders Love Right Now
www.thestreet.com - January 13 at 4:04 PM
finance.yahoo.com logoCan The Uptrend Continue for Aquinox Pharmaceuticals (AQXP)? - Yahoo Finance
finance.yahoo.com - January 10 at 3:39 PM

Social

Chart

Aquinox Pharmaceuticals (AQXP) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff